Journal Information

Statistics

Follow this link to access the full text of the article

423
CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES
H. Quacha, A. Nookab, O. Samoylovac, C.P. Vennerd, T. Facone, A. Spencerf, S.Z. Usmanig, K. Weiselh, M. Mateosi, K. Kimj, S. Grosickik, K. Suzukil, S. Delimpasim, M. Obrejan, A. Zahlten-Kumelin
a University of Melbourne, St. Vincent's Hospital, Melbourne, Australia
b Winship Cancer Institute, Emory University, Atlanta, United States
c Nizhniy Novgorod Region Clinical Hospital, Nizhny Novgorod, Russia
d Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
e Hôpital Claude Huriez, Lille, France
f Alfred Health-Monash University, Melbourne, Australia
g Atrium Health, Charlotte, United States
h University Medical Center Hamburg-Eppendorf, Hamburg, Germany
i University Hospital Salamanca/IBSAL, Salamanca, Spain
j Sungkyunkwan University, Samsung Medical Center, Seoul, Korea
k Silesian Medical University, Katowice, Poland
l Japanese Red Cross Medical Center, Tokyo, Japan
m General Hospital Evangelismos, Athens, Greece
n Amgen Inc., Thousand Oaks, United States
Read
1092
Times
was read the article
411
Total PDF
503
Total HTML
178
Total EPUB
Share statistics
Article information
ISSN: 25311379
Original language: English
The statistics are updated each day
Year/Month Html Pdf Epub Total
2021 December 6 5 3 14
2021 November 29 34 5 68
2021 October 34 32 5 71
2021 September 35 38 9 82
2021 August 27 34 11 72
2021 July 34 42 27 103
2021 June 47 36 5 88
2021 May 34 34 7 75
2021 April 136 65 14 215
2021 March 45 35 12 92
2021 February 21 13 6 40
2021 January 13 13 4 30
2020 December 22 17 3 42
2020 November 20 13 67 100
Show all

Follow this link to access the full text of the article

Idiomas
Hematology, Transfusion and Cell Therapy

Subscribe to our newsletter